AI-Powered Therapy Extends Lifespan by 70% in Preclinical Aging Models
Immorta Bio combines senolytics and stem cell revival with AI to achieve 70%+ lifespan extension in animal models.
Summary
Immorta Bio has unveiled an AI-guided therapeutic approach targeting two major drivers of aging: the buildup of senescent (zombie) cells and the decline of stem cell function. Using its SenoVax and StemCellRevivify platforms, the company reported preclinical results showing more than 70% mean lifespan extension and over 80% median lifespan extension in aging animal models. Alongside longer life, treated animals showed improvements in organ function, inflammation levels, physical performance, and regenerative capacity. The company collaborates with leading research institutions including the Buck Institute and Cedars-Sinai. While still in early preclinical stages, the dual-target strategy and AI-personalization angle represent a notable convergence of cutting-edge longevity science.
Detailed Summary
Immorta Bio is pursuing one of the most ambitious longevity therapy strategies to date, combining two complementary biological targets with artificial intelligence to personalize treatment. The company recently presented findings at MedTech World North America, drawing attention for dramatic preclinical outcomes in validated aging models.
The core findings are striking: animals treated with Immorta Bio's dual-platform approach showed more than 70% mean lifespan extension and more than 80% median lifespan extension. Beyond simply living longer, treated subjects also demonstrated measurable improvements in regeneration, inflammation control, organ function, and physical performance — suggesting healthspan gains alongside lifespan extension.
The two proprietary platforms address distinct but interconnected aging mechanisms. SenoVax targets senescent cells — aged, dysfunctional cells that accumulate over time and drive chronic inflammation and tissue damage. StemCellRevivify focuses on restoring stem cell number and potency, which naturally decline with age and undermine the body's repair capacity. Attacking both simultaneously may produce synergistic benefits that single-target approaches miss.
Artificial intelligence is central to the company's personalization strategy, theoretically allowing therapies to be tailored to an individual's biological profile rather than applied as a one-size-fits-all intervention. Collaborations with the Buck Institute for Research on Aging, Cedars-Sinai Medical Center, UC San Diego, and the University of Miami lend institutional credibility to the program.
However, several important caveats apply. These results are preclinical — derived from animal models, not human trials — and the leap to human efficacy remains unproven. No peer-reviewed publication was cited, and the announcement appears to be largely promotional in nature. Investors and health enthusiasts should treat these figures with cautious optimism and await clinical trial data before drawing conclusions about human applicability.
Key Findings
- Preclinical models showed over 70% mean and 80% median lifespan extension using the dual-platform therapy.
- SenoVax targets senescent cell accumulation; StemCellRevivify restores stem cell number and function.
- Treated animals showed improvements in inflammation, organ function, regeneration, and physical performance.
- AI is used to personalize therapeutic dosing and targeting based on individual biological profiles.
- Collaborations include Buck Institute, Cedars-Sinai, UC San Diego, and University of Miami.
Methodology
This is a news report summarizing a company press presentation, not a peer-reviewed study. No primary publication was cited. Evidence is based on company-reported preclinical findings presented at a medtech conference, which have not been independently verified.
Study Limitations
All results are preclinical and have not been published in peer-reviewed literature. Company-reported figures from conference presentations may reflect best-case outcomes and lack independent validation. Human translation of animal lifespan data is historically difficult and often disappoints.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.